Opportunity Information: Apply for PA 18 496
This funding opportunity (PA 18-496) is an administrative supplement program from the National Cancer Institute (NCI), under the Department of Health and Human Services and the NIH, created as part of the Cancer Moonshot initiative. It was developed in response to recommendations from the Cancer Moonshot Blue Ribbon Panel, which identified high-impact scientific opportunities that could be accelerated through targeted federal investment. The central idea is to speed up translational cancer research by strengthening the bridge between discovery work and the preclinical testing needed to justify and design future human studies.
The supplement specifically supports new collaborations between investigators who are not currently part of the Patient-Derived Xenograft (PDX) Development and Trial Centers Research Network (PDXNet) and investigators who are part of PDXNet. PDXNet is an NCI-created network of specialized centers that develop and use patient-derived xenografts (PDX) and other patient-derived cancer models at scale. These models are built from patient tumor tissue and grown in immunocompromised mice (or related systems), with the goal of better preserving key biological features of the original tumor compared with many traditional cancer cell line models. By providing access to large, well-characterized collections of PDX models and the expertise housed within PDXNet, NCI is encouraging outside NCI-funded researchers to test promising therapeutic concepts more rigorously and more quickly in preclinical settings that may better predict clinical performance.
The purpose of the administrative supplement is not to create an entirely new standalone research project, but to add funds to an existing, active NCI grant or cooperative agreement so the parent project can take on a defined set of collaborative activities that still fit within the scientific scope of the original award. In other words, the proposed supplement work is expected to align with and extend the aims of the parent award, while leveraging PDXNet resources to strengthen preclinical evaluation. The research supported should be aimed at improving preclinical testing of novel therapeutic concepts, particularly those relevant to NCI investigational new drug (IND) agents. These are drug candidates that NCI is developing in collaboration with pharmaceutical partners and that may be positioned for testing in NCI-sponsored early phase clinical trials. While the supplement itself is labeled "Clinical Trial Not Allowed," the intended trajectory is that successful preclinical results could inform and support later clinical testing sponsored by NCI.
From a practical standpoint, this opportunity is structured as a discretionary grant supplement mechanism, with an award ceiling listed at $125,000 and an expected number of awards of 4 in the referenced cycle. The original closing date shown for this specific announcement was March 1, 2018, and the creation date was December 15, 2017, indicating it was tied to a particular administrative supplement round rather than an always-open mechanism. The listing includes multiple CFDA numbers associated with NCI research support (93.393, 93.394, 93.395, 93.396, 93.399), reflecting the breadth of NCI programs that could potentially serve as the parent award base, depending on the specific grant type and institute alignment.
Eligibility is broad in the sense that it includes many common applicant organization types (state, county, and local governments; public and private institutions of higher education; tribal governments and tribal organizations; certain housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations other than small businesses; small businesses; and other entities as described in the full eligibility text). However, because this is an administrative supplement, the true functional eligibility hinges on already holding an active NCI-funded grant or cooperative agreement that can receive supplemental funds, and proposing a collaboration that fits within that parent award's scope while incorporating meaningful participation from PDXNet investigators and use of PDXNet model collections and capabilities.
In summary, this administrative supplement opportunity is designed to catalyze cross-team, interdisciplinary work that combines existing NCI-funded research programs with the specialized infrastructure of PDXNet. The goal is to generate stronger, more clinically relevant preclinical evidence for innovative therapeutic ideas, particularly those connected to NCI IND agents, so that the most promising approaches can be advanced more efficiently toward NCI-sponsored early phase clinical trials, even though the supplement-supported activities themselves cannot be clinical trials.Apply for PA 18 496
- The Department of Health and Human Services, National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the PDX Development and Trial Centers Research Network (PDXNet)(Admin Suppl - Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393, 93.394, 93.395, 93.396, 93.399.
- This funding opportunity was created on Dec 15, 2017.
- Applicants must submit their applications by Mar 01, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $125,000.00 in funding.
- The number of recipients for this funding is limited to 4 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is PA 18-496?
PA 18-496 is a National Cancer Institute (NCI) administrative supplement funding opportunity created under the Department of Health and Human Services (HHS) and the National Institutes of Health (NIH) as part of the Cancer Moonshot initiative. It is designed to accelerate translational cancer research by strengthening the link between discovery science and the preclinical testing needed to justify and design later human studies.
What is the main goal of this administrative supplement?
The main goal is to speed up and strengthen preclinical evaluation of promising therapeutic concepts by enabling new collaborations that leverage Patient-Derived Xenograft (PDX) models and related patient-derived cancer models housed within the NCI-supported PDX Development and Trial Centers Research Network (PDXNet).
Is this funding for a brand-new standalone research project?
No. This is an administrative supplement, meaning it adds funds to an existing, active NCI grant or cooperative agreement. The proposed supplement activities are expected to align with and remain within the scientific scope of the parent award, while extending or strengthening that work through a defined collaboration with PDXNet.
Who is this supplement intended to support?
It specifically supports new collaborations between investigators who are not currently part of PDXNet and investigators who are part of PDXNet. The intent is to connect outside NCI-funded researchers with PDXNet expertise and model resources to improve the rigor and speed of preclinical testing.
What is PDXNet?
PDXNet is an NCI-created network of specialized centers that develop and use patient-derived xenografts (PDX) and other patient-derived cancer models at scale. PDX models are generated from patient tumor tissue and grown in immunocompromised mice (or related systems) to better preserve key biological characteristics of the original tumor compared with many traditional cell line models.
Why are patient-derived xenograft (PDX) models emphasized in this program?
The program emphasizes PDX and other patient-derived models because they can better retain important tumor features from the patient source tumor, which can make preclinical testing more clinically relevant. By using large, well-characterized collections of PDX models and the specialized expertise within PDXNet, the program aims to produce preclinical evidence that may better predict clinical performance.
What kinds of research activities does the supplement aim to support?
The supplement is aimed at improving preclinical testing of novel therapeutic concepts, particularly by leveraging PDXNet model collections and capabilities. The supported work is intended to strengthen the preclinical evidence base needed to inform potential future human studies.
How does this opportunity relate to the Cancer Moonshot initiative?
This opportunity was developed as part of the Cancer Moonshot initiative and was responsive to recommendations from the Cancer Moonshot Blue Ribbon Panel. The underlying idea is to accelerate high-impact scientific opportunities through targeted federal investment, especially opportunities that can speed translation from discovery to preclinical validation and, ultimately, to clinical testing.
Are clinical trials allowed under this supplement?
No. The supplement is labeled "Clinical Trial Not Allowed." The supported activities themselves cannot be clinical trials.
If clinical trials are not allowed, what is the intended trajectory for successful projects?
Even though clinical trials cannot be conducted with supplement funds, the intended trajectory is that strong preclinical results generated through the collaboration could inform and support later clinical testing sponsored by NCI, including early phase clinical trials.
What are NCI investigational new drug (IND) agents in the context of this announcement?
In this announcement, NCI IND agents refer to drug candidates that NCI is developing in collaboration with pharmaceutical partners and that may be positioned for testing in NCI-sponsored early phase clinical trials. The supplement particularly highlights preclinical testing that is relevant to these NCI IND agents.
What is the maximum award amount for this supplement?
The award ceiling listed for this supplement mechanism is $125,000.
How many awards were expected in the referenced cycle?
The announcement referenced an expected number of 4 awards for that cycle.
What were the key dates associated with this specific opportunity?
The creation date shown for the announcement was December 15, 2017, and the original closing date shown was March 1, 2018. This indicates it was tied to a specific administrative supplement round rather than an always-open mechanism.
What types of organizations are listed as eligible applicants?
The listed eligibility includes a broad range of organization types, such as state, county, and local governments; public and private institutions of higher education; tribal governments and tribal organizations; certain housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations other than small businesses; small businesses; and other entities as described in the full eligibility text.
What is the most important practical eligibility requirement for this supplement?
Because this is an administrative supplement, functional eligibility depends on having an existing, active NCI-funded grant or cooperative agreement that can receive supplemental funds. The proposed supplement activities must fit within the scientific scope of that parent award and include meaningful collaboration with PDXNet investigators and use of PDXNet resources.
Does the supplement require collaboration with PDXNet investigators?
Yes. The supplement is designed to support new collaborations between non-PDXNet investigators and PDXNet investigators, specifically to leverage PDXNet model collections and capabilities.
What does it mean for supplement work to be "within the scientific scope" of the parent award?
It means the supplement activities should align with and extend the aims of the existing NCI-funded parent project, rather than introducing an unrelated line of research. The supplement is intended to add collaborative preclinical testing activities that strengthen the parent project using PDXNet resources.
What is the role of PDXNet resources in the proposed work?
PDXNet provides access to large, well-characterized collections of PDX models and specialized expertise for using patient-derived cancer models at scale. The supplement encourages using these resources to test promising therapeutic ideas more rigorously and efficiently in preclinical settings.
Which CFDA numbers are associated with this opportunity?
The listing includes multiple CFDA numbers associated with NCI research support: 93.393, 93.394, 93.395, 93.396, and 93.399. These reflect the breadth of NCI programs that could potentially serve as the parent award base, depending on the specific grant type and institute alignment.
Why does the announcement include multiple CFDA numbers?
The multiple CFDA numbers indicate that the supplement could be relevant across a range of NCI research support programs, suggesting that different types of existing NCI awards (depending on program and alignment) could potentially serve as the eligible parent award for the supplement.
What problem is this supplement trying to solve in the translational research pipeline?
It targets the gap between discovery research and the preclinical testing needed to justify and design future human studies. By strengthening collaborative preclinical evaluation using PDXNet infrastructure, the program aims to generate stronger evidence sooner for innovative therapeutic concepts.
How does this supplement encourage faster translation to the clinic if it does not fund clinical trials?
It focuses on producing higher-quality, more clinically relevant preclinical data that can support later decision-making and trial design. The concept is that improved preclinical testing can help identify the most promising approaches for advancement into NCI-sponsored early phase clinical trials, even though the supplement itself cannot fund those trials.
Is the program described as discretionary, and what does that imply in this context?
Yes. The opportunity is described as a discretionary grant supplement mechanism. In the context of the provided information, this signals that the supplement awards are not automatic and are made as part of a targeted, time-bound administrative supplement round with a limited number of awards.
Browse more opportunities from the same category: Education, Health
Next opportunity: DRL FY17/18 Cuba SOI
Previous opportunity: U.S. Fish and Wildlife Service Quagga Mussel Containment in the Lower Colorado River (Lake Havasu/Lake Pleasant)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 18 496
Applicants also applied for:
Applicants who have applied for this opportunity (PA 18 496) also looked into and applied for these:
| Funding Opportunity |
|---|
| Identification of Biomarkers of HIV-1 Pathogenesis and Substance Abuse Comorbidity (R01- Clinical Trial Not Allowed) Apply for RFA DA 18 023 Funding Number: RFA DA 18 023 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Distance Learning and Telemedicine Grant Program Apply for RUS 18 01 DLT Funding Number: RUS 18 01 DLT Agency: Department of Agriculture, Utilities Programs Category: Education, Health Funding Amount: $500,000 |
| Administrative Supplements to NCI Grant and Cooperative Agreement Awards to Support Collaborations with the Drug Resistance and Sensitivity Network (DRSN)(Admin Supp Clinical Trial Not Allowed) Apply for PAR 18 752 Funding Number: PAR 18 752 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| NCI Community Oncology Research Program (NCORP) Community Sites (UG1 Clinical Trial Required) Apply for RFA CA 18 016 Funding Number: RFA CA 18 016 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Community Oncology Research Program (NCORP) Minority/Underserved Community Sites (UG1 Clinical Trial Required) Apply for RFA CA 18 017 Funding Number: RFA CA 18 017 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required) Apply for RFA CA 18 015 Funding Number: RFA CA 18 015 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01 Clinical Trial Required) Apply for RFA CA 19 017 Funding Number: RFA CA 19 017 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| HIV/AIDS High Priority Drug Abuse Research (R01 Clinical Trial Optional) Apply for PAS 18 915 Funding Number: PAS 18 915 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium (U54 Clinical Trial Not Allowed) Apply for RFA CA 19 016 Funding Number: RFA CA 19 016 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $1,600,000 |
| Administrative Supplements to Cancer Center Support Grants to Strengthen the Research, Training, and Outreach Capacity of the Geographic Management of Cancer Health Disparities Program (Admin Suppl - Clinical Trial Not Allowed) Apply for PA 18 934 Funding Number: PA 18 934 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| The National Drug Abuse Treatment Clinical Trials Network (UG1 Clinical Trial Optional) Apply for RFA DA 19 008 Funding Number: RFA DA 19 008 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| NLM Grants for Scholarly Works in Biomedicine and Health (G13 Clinical Trial Not Allowed) Apply for PAR 19 032 Funding Number: PAR 19 032 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $50,000 |
| Administrative Supplements to Cancer Center Support Grants to Strengthen NCI-Supported Community Outreach Capacity through Community Health Educators of the National Outreach Network (Admin Suppl Clinical Trial Not Allowed) Apply for PA 19 035 Funding Number: PA 19 035 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $125,000 |
| Immuno-Oncology Translation Network (IOTN): Immuno-engineering to Improve Immunotherapy (i3) Centers (U54 Clinical Trial Not Allowed) Apply for RFA CA 19 013 Funding Number: RFA CA 19 013 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $900,000 |
| HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Coordination and Translation Center (U2C Clinical Trial Optional) Apply for RFA DA 19 024 Funding Number: RFA DA 19 024 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $2,500,000 |
| HEAL Initiative: Justice Community Opioid Innovation Network (JCOIN) Methodology and Advanced Analytics Resource Center (U2C Clinical Trial Not Allowed) Apply for RFA DA 19 023 Funding Number: RFA DA 19 023 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $2,500,000 |
| NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed) Apply for RFA CA 19 029 Funding Number: RFA CA 19 029 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required) Apply for RFA CA 19 030 Funding Number: RFA CA 19 030 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trials Not Allowed) Apply for RFA CA 19 022 Funding Number: RFA CA 19 022 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R21 Clinical Trials Not Allowed) Apply for RFA CA 19 021 Funding Number: RFA CA 19 021 Agency: Department of Health and Human Services, National Institutes of Health Category: Education, Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 18 496", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.